Abstract
AbstractRetinal imaging technologies have advanced rapidly over the past few years, and with their development their ability to be used as endpoints and even surrogate makers of eye and brain diseases. Optical Coherence Tomography (OCT) is now a routine test offered around the world. Both hardware and software advances including fast acquisition speeds, big data from a single patient scan and algorithms (with and without AI) account for recognition of the value of OCT imaging in CNS disease. Adaptive optics and OCT angiography have been also utilized for assessment of disease. The technology that has been developed to detect apoptosing retinal cells (DARC) has completed Phase 2 trials including patients with AMD, optic neuritis, Down's dementia and glaucoma. For all neurodegenerative conditions, the unmet need is to identify early disease. This can only be possible if we are able to screen to find the earliest stages of disease. Retinal imaging provides an opportunity to do this.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
